Patents Face 'Real Threat' From Inter Partes Review; PTAB Open To Change
Executive Summary
Pfizer attorney says brand-name drug companies no longer can rely on the outcome of ANDA litigation to predict date of generic competition; PTAB chief judge observes that there is 'opportunity to get some more certainty for patent owners.'
You may also be interested in...
Pfizer Keeps IPR Winning Streak; Court Affirms Ruling On Tygacil Patent
Federal Circuit finds Patent Trial and Appeal Board was correct in deciding composition patent on antibiotic was not obvious; Pfizer's inter partes review petition challenging Alzheimer's-related patent ended in settlement.
Supreme Court Upholds IPR Standard Making Patent Invalidation Easier; Will Congress Reverse?
High court says inconsistent decisions by Patent Trial and Appeal Board and district court are okay; House and Senate bills would eliminate the broad standard but opposition by tech community could doom passage.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.